From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Released on Friday, February 7, the January jobs report showed resilience in the labor market with higher-than-expected wage ...

So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Inspire Medical shares dipped — but have since mostly recovered — following news of a government investigation following Q4 ...

Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...